LRP6 and atherosclerosis: Recently, a reduction in Wnt-mediated transcription resulting from mutations in LRP6 has been confirmed to lead to several features of metabolic syndrome, including atherosclerosis (50), diabetes (55), hyperlipidemia (50, 53), and hypertension (54), but not obesity.